Omaveloxolone
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 126 publications
Pharmacological treatments for Friedreich ataxia.
Journal: The Cochrane database of systematic reviews
Published: May 12, 2026
Inhibition of smooth muscle phenotypic modulation by bardoxolone methyl, omaveloxolone, and cinnamaldehyde is Nrf-2 dependent.
Journal: Advances in redox research
Published: March 27, 2026
Application of a Blood-Brain Barrier Organ-on-a-Chip Model for Assessment of Countermeasure Efficiency Against Eastern Equine Encephalitis Virus.
Journal: Viruses
Published: February 26, 2026
NRF2 as a Therapeutic Target in Dermatological Disorders: Mechanisms and Molecules.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: February 03, 2026
Pharmacotherapy of neuromuscular diseases : what's new in 2025
Journal: Revue medicale suisse
Published: January 16, 2026
Advanced Heart Failure in Friedreich's Ataxia: A Story of Challenges, Opportunities, and Hope.
Journal: JACC. Case reports
Published: January 07, 2026
The Role of Natural Product Chemistry in Drug Discovery: Two Decades of Progress and Perspectives.
Journal: Journal of natural products
Published: December 26, 2025
Targeting frataxin deficiency in DRG neurons and fibroblasts: omaveloxolone restores metabolic and iron balance to reduce ferroptosis.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: December 03, 2025
Discovery of a novel Nrf2 activator that modulates mitochondrial function in neurons by regulating DHRS3-Nrf2 interaction after ischemic stroke.
Journal: Theranostics
Published: November 18, 2025
Last Updated: 06/30/2026